Full archive

Point-of-care *CYP2C19* genotyping — CRISPR assay

Personalized dosing in obese patients — *CYP3A4* phenotyping

Opioid toxicity from CYP3A4 drug-drug interaction

CYP2D6 — Haplo2D6 web tool for automated metabolizer haplotype and phenotype inference from genotyping data

Pharmacogenomic differentiation between East Asian and European populations — evolutionary disparities and implications for PGx panels

Plasma CYP induction — RT-qPCR on exosomes as non-invasive biomarker of enzymatic induction and drug-drug interactions

Gastroesophageal reflux disease — PPI failure, CYP2C19 rapid/ultrarapid metabolizer prevalence

CYP2C19 phenoconversion under drug inhibitors after percutaneous coronary intervention

Rheumatoid arthritis — TNF inhibitor non-response according to FTO genotype and BMI

Pediatric mental health conditions treated with sertraline — side effects and symptom improvement by CYP450 genotype

Statin-associated muscle symptoms (SAMS) — genetic determinants related to the coenzyme Q10 pathway

PGx allele frequencies (CYP2C9, CYP2C19, CYP2D6, SLCO1B1) in the Yogyakarta population (Indonesia)

Lipid response to statins by APOE genotype — meta-analysis

Acute coronary syndrome (ACS) — MACE risk under clopidogrel

Psychiatric disorders — economic efficiency of PGx genotyping

Thiopurines during pregnancy — inflammatory bowel disease

Adolescent-onset schizophrenia — social cognition and *CYP2D6* metabolism

Clopidogrel resistance — recurrent ischemic stroke

Health economics of preemptive pharmacogenetic testing

Major depressive disorder — pharmacogenetics-guided antidepressant prescribing

Renal transplantation — preemptive pharmacogenetics

Fluoropyrimidine toxicity — *DPYD* variants in indigenous populations

Fluoropyrimidine and irinotecan toxicity

CYP2C19 functional phenotyping — validation of pantoprazole/4-desmethylpantoprazole-sulfate metabolic ratio as phenotyping probe

Tacrolimus — pharmacogenetic prediction of pharmacokinetic phenotype (C0/D/W) in kidney transplantation by integrating CYP3A4/CYP3A5 variants and clinical factors

CYP3A4 drug-drug interaction — voriconazole and posaconazole impact on cyclosporine in pediatric allogeneic HSCT recipients

DPYD and UGT1A1 — clinical implementation of pharmacogenomic testing guiding fluoropyrimidine and irinotecan chemotherapy

Complete DPD deficiency (DPYD*2A homozygous) — ultra-low-dose capecitabine

Depression / Anxiety

Pharmacogenetics in intensive care

Pharmacogenetics — drug metabolism

Colorectal cancer — fluoropyrimidine toxicity

Unruptured intracranial aneurysm treated by stent-assisted coil embolization

SLCO1B1 phenoconversion in clinical routine: detection by endogenous biomarker

Under-implementation of clopidogrel pharmacogenetics in cardiology

Voriconazole toxicity in pediatric leukemia and HSCT — prediction by CYP2C19 genotype

Eltrombopag-induced hepatotoxicity (thrombopoietin receptor agonist) — role of UGT1A1 genotype

Epilepsy in Asia — pharmacogenomics of antiepileptic drugs (HLA-B*15:01, HLA-A*31:01, SCN1A/CYP2C19)

Thiopurine toxicity (mercaptopurine, azathioprine, thioguanine) — severe myelotoxicity

Major depressive disorder (MDD) — antidepressant adverse drug reactions

Depression in military veterans — implementation of multigene PGx genotyping

CYP2C19 metabolic variability — new alleles in Chinese Han population

Clinical implementation of WGS for pharmacogenetics — analytical validation

Post-PCI antiplatelet therapy — debate on CYP2C19 genotyping generalization

Diabetic microvascular complications — influence of drug-gene interactions on risk

Cancer — prevention of 5-fluoropyrimidine toxicity

CYP2D6 PGx variability and antipsychotic tolerability in adolescent schizophrenia patients

Adverse drug reactions — burden of metabolic pathway inhibition

Primary care pharmacogenetics — Māori tribal ethical framework

Idiosyncratic drug-induced liver injury (iDILI) — genetic susceptibility

Breast cancer — tamoxifen and *CYP2D6* phenotyping by NGS

Pharmacogenetics — benchmark of star-allele calling tools

Cardiovascular diseases / pharmacogenomics

Warfarin anticoagulation / interindividual variability

Drug-drug interactions / FDA labeling

Tacrolimus PK variability in pediatric renal transplantation

Pharmacogenomics of anti-infective therapies

6-mercaptopurine — metabolic profiles and clinical toxicity by combined TPMT/NUDT15 phenotype in Thai pediatric ALL

Post-PCI — CYP2C19 genotype-guided P2Y12 inhibitor therapy optimization

IBD — thiopurine monitoring, TPMT/NUDT15 PGx and therapeutic drug monitoring

Aripiprazole — metabolic abnormalities by CYP2D6 phenotype and phenoconversion

Tuberculosis — NAT2 acetylation variability, isoniazid dose individualization in elderly patients

Invasive fungal infections — voriconazole

Efavirenz in HIV/tuberculosis patients — *CYP2B6* 516 G>T polymorphism

Clozapine — CYP1A2 phenoconversion by smoking and smoking cessation